[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2024-06-01 DOI:10.19746/j.cnki.issn.1009-2137.2024.03.017

Rui Guo, Xu-Xing Shen, Yuan Xia, Yuan-Yuan Jin, Jian-Yong Li, Li-Juan Chen, Hai-Rong Qiu

{"title":"[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].","authors":"Rui Guo, Xu-Xing Shen, Yuan Xia, Yuan-Yuan Jin, Jian-Yong Li, Li-Juan Chen, Hai-Rong Qiu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.017","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the prognostic value of del(1p32) in patients with newly diagnosed multiple myeloma (MM).Methods: The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed. Clinical characteristic combined with genetic features, especially del(1p32), were analyzed for survival and prognostic of patients.Results: Among the 341 patients with newly diagnosed MM, 24(7.0%) patients were del(1p32) positive. The progression-free survival (PFS) and overall survival (OS) were significantly shorter in MM patients with del(1p32) than those without del(1p32) (PFS: P < 0.001;OS: P < 0.001). The COX proportional-hazards model showed that del (1p32) was an independent risk factor for PFS and OS of patients with MM. The patients with both 1q21 gain/amplification and del(1p32), as \"double-hit chromosome 1\", have worse prognosis than those with only 1q21 gain/amplification or only del(1p32) (PFS: P < 0.001; OS: P < 0.001).Conclusion: Del(1p32) is an independent risk factor for PFS and OS of patients with MM. Del(1p32) detection should be widely used in the prognostic analysis for newly diagnosed MM patients.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze the prognostic value of del(1p32) in patients with newly diagnosed multiple myeloma (MM).

Methods: The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed. Clinical characteristic combined with genetic features, especially del(1p32), were analyzed for survival and prognostic of patients.

Results: Among the 341 patients with newly diagnosed MM, 24(7.0%) patients were del(1p32) positive. The progression-free survival (PFS) and overall survival (OS) were significantly shorter in MM patients with del(1p32) than those without del(1p32) (PFS: P < 0.001;OS: P < 0.001). The COX proportional-hazards model showed that del (1p32) was an independent risk factor for PFS and OS of patients with MM. The patients with both 1q21 gain/amplification and del(1p32), as "double-hit chromosome 1", have worse prognosis than those with only 1q21 gain/amplification or only del(1p32) (PFS: P < 0.001; OS: P < 0.001).

Conclusion: Del(1p32) is an independent risk factor for PFS and OS of patients with MM. Del(1p32) detection should be widely used in the prognostic analysis for newly diagnosed MM patients.

查看原文本刊更多论文

[Del(1p32) 在新诊断多发性骨髓瘤患者中的预后价值]。

目的分析del(1p32)在新诊断多发性骨髓瘤（MM）患者中的预后价值：方法：回顾性分析江苏省人民医院收治的341例新近确诊的多发性骨髓瘤患者的临床资料。方法：回顾性分析江苏省人民医院收治的341例新近确诊的多发性骨髓瘤患者的临床资料，结合临床特征和遗传学特征，尤其是del(1p32)，分析患者的生存率和预后：结果：在341例新诊断的MM患者中，有24例（7.0%）del(1p32)阳性。有del(1p32)的MM患者的无进展生存期（PFS）和总生存期（OS）明显短于无del(1p32)的患者（PFS：P < 0.001；OS：P < 0.001）。COX比例危险模型显示，del（1p32）是影响MM患者PFS和OS的独立危险因素。同时具有1q21增益/扩增和del（1p32）的 "1号染色体双击 "患者比仅具有1q21增益/扩增或仅具有del（1p32）的患者预后更差（PFS：P＜0.001；OS：P＜0.001）：结论：Del(1p32)是影响MM患者PFS和OS的独立危险因素。结论：Del(1p32)是MM患者PFS和OS的独立危险因素，Del(1p32)检测应广泛应用于新诊断MM患者的预后分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊